AI Science Tracker

Rentosertib: AI-designed drug reports Phase IIa results in pulmonary fibrosis

Insilico Medicine · 3 Jun 2025 · medicine

Discovery

Rentosertib: AI-designed drug reports Phase IIa results in pulmonary fibrosis

In the GENESIS-IPF study of 71 patients with idiopathic pulmonary fibrosis at 22 centers (placebo versus three doses, 12 weeks), the 60 mg/day group had a mean FVC change of +98.4 mL versus −20.3 mL for placebo. Groups were small, so larger studies are needed; biomarker analysis was exploratory.

Technology: Pharma.AI (generative AI for targets and molecules)

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: Phase 2a, multicenter, double-blind, randomized, placebo-controlled, 71 patients for 12 weeks. Primary endpoint (patients with at least one treatment-emergent adverse event) was similar across arms: 70.6% to 83.3%. Treatment-related serious adverse events were low and comparable.
  • Still unknown: Efficacy in larger and longer trials is not established by this phase 2a study.
  • AI role: Generative AI was used to discover the TNIK target and the small-molecule inhibitor, per the paper's title and abstract.

Evidence sources: https://doi.org/10.1038/s41591-025-03743-2

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 239 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.